Literature DB >> 9821153

NMDA and AMPA receptors evoke transmitter release from noradrenergic axon terminals in the rat spinal cord.

E Sundström1, L Holmberg, F Souverbie.   

Abstract

N-methyl-D-aspartate (NMDA) stimulated release of [3H]noradrenaline (NA) from prelabelled rat spinal cord slices. The release was partially insensitive to tetrodotoxin (TTX) and was inhibited by the NMDA antagonist MK-801. Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) also evoked release of [3H]NA, which was enhanced by blocking AMPA receptor desensitization with cyclothiazide. AMPA-evoked release was inhibited by the non-NMDA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)-quinoxaline (NBQX) but was not affected by TTX. NMDA and AMPA showed synergistic effects, indicating co-existence of NMDA and AMPA receptors on noradrenergic terminals. Kainate evoked [3H]NA release only at high concentrations and the release was not potentiated by blocking kainate receptor desensitization with concanavalin A. Thus, the results indicate that there are stimulatory presynaptic NMDA and AMPA receptors on noradrenergic axon terminals in the spinal cord and that they interact synergistically to evoke release of [3H]NA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9821153     DOI: 10.1023/a:1020967601813

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  38 in total

1.  Involvement of glutamate receptor subtypes in l-[(3)H]noradrenaline release from cerebral cortical and hippocampal slices of mice.

Authors:  X H Zhao; Y Kitamura; Y Nomura
Journal:  Neurochem Int       Date:  1990       Impact factor: 3.921

2.  Presynaptic NMDA receptors stimulate noradrenaline release in the cerebral cortex.

Authors:  K Fink; H Bönisch; M Göthert
Journal:  Eur J Pharmacol       Date:  1990-08-21       Impact factor: 4.432

Review 3.  Peripheral and spinal mechanisms of nociception.

Authors:  J M Besson; A Chaouch
Journal:  Physiol Rev       Date:  1987-01       Impact factor: 37.312

4.  GABA and potassium effects on corticospinal and primary afferent tracts of neonatal rat spinal dorsal columns.

Authors:  O Honmou; K Sakatani; W Young
Journal:  Neuroscience       Date:  1993-05       Impact factor: 3.590

5.  2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia.

Authors:  M J Sheardown; E O Nielsen; A J Hansen; P Jacobsen; T Honoré
Journal:  Science       Date:  1990-02-02       Impact factor: 47.728

6.  Norepinephrine modulates excitability of neonatal rat optic nerves through calcium-mediated mechanisms.

Authors:  O Honmou; W Young
Journal:  Neuroscience       Date:  1995-03       Impact factor: 3.590

7.  Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents.

Authors:  K A Yamada; C M Tang
Journal:  J Neurosci       Date:  1993-09       Impact factor: 6.167

8.  Depolarizing responses to glycine, beta-alanine and muscimol in isolated optic nerve and cuneate nucleus.

Authors:  M A Simmonds
Journal:  Br J Pharmacol       Date:  1983-07       Impact factor: 8.739

9.  Phencyclidine selectively inhibits N-methyl-D-aspartate-induced hippocampal [3H]norepinephrine release.

Authors:  S M Jones; L D Snell; K M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030

10.  Differential effects of excitatory amino acid antagonists on dorsal horn nociceptive neurones in the rat.

Authors:  A H Dickenson; A F Sullivan
Journal:  Brain Res       Date:  1990-01-01       Impact factor: 3.252

View more
  2 in total

1.  Retrograde modulation of transmitter release by postsynaptic subtype 1 metabotropic glutamate receptors in the rat cerebellum.

Authors:  C Levenes; H Daniel; F Crepel
Journal:  J Physiol       Date:  2001-11-15       Impact factor: 5.182

Review 2.  Presynaptic release-regulating NMDA receptors in isolated nerve terminals: A narrative review.

Authors:  Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2021-02-02       Impact factor: 9.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.